Zacks Research Has Positive Outlook of Prothena Q1 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Zacks Research boosted their Q1 2025 earnings per share estimates for Prothena in a note issued to investors on Wednesday, March 12th. Zacks Research analyst E. Bagri now expects that the biotechnology company will earn ($1.06) per share for the quarter, up from their previous estimate of ($1.33). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($4.04) EPS.

Prothena (NASDAQ:PRTA) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.06). The firm had revenue of $2.12 million during the quarter, compared to analyst estimates of $7.53 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%.

A number of other equities research analysts also recently issued reports on PRTA. Oppenheimer increased their price target on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. StockNews.com raised Prothena from a “sell” rating to a “hold” rating in a research report on Monday, February 24th. Piper Sandler increased their price target on Prothena from $94.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Bank of America reduced their price target on Prothena from $26.00 to $22.00 and set a “neutral” rating on the stock in a research report on Thursday, December 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Prothena currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Prothena Price Performance

Shares of NASDAQ:PRTA opened at $12.83 on Monday. The company has a market capitalization of $690.60 million, a P/E ratio of -5.58 and a beta of -0.02. Prothena has a 1 year low of $11.70 and a 1 year high of $26.45. The business’s 50 day simple moving average is $14.38 and its 200 day simple moving average is $15.98.

Institutional Investors Weigh In On Prothena

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP bought a new position in shares of Prothena in the 3rd quarter valued at $484,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Prothena by 8.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,492 shares of the biotechnology company’s stock worth $2,049,000 after acquiring an additional 9,666 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Prothena in the 3rd quarter valued at about $210,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Prothena in the 3rd quarter valued at about $432,000. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Prothena by 3.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock valued at $1,440,000 after buying an additional 3,163 shares during the period. 97.08% of the stock is currently owned by institutional investors.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.